Dengue fever

Lore & Background

Dengue is spread by several species of female mosquitoes of the Aedes genus, principally Aedes aegypti. The virus has four confirmed serotypes; infection with one type usually gives lifelong immunity to that type, but only short-term immunity to the others. Subsequent infection with a different type increases the risk of severe complications, so-called antibody-dependent enhancement. Most cases of dengue fever are either asymptomatic or manifest mild symptoms. Symptoms typically begin 3 to 14 days after infection and may include a high fever, headache, vomiting, muscle and joint pains, and a characteristic skin itching and skin rash. Recovery generally takes two to seven days. In a small proportion of cases, the disease develops into severe dengue with bleeding, low levels of blood platelets, blood plasma leakage, and dangerously low blood pressure. Infection can be prevented by mosquito elimination and the prevention of mosquito bites. Treatment is symptomatic, as there is no specific treatment for dengue fever. Severe cases require hospitalisation and supportive care including fluid administration.

Reader's Guide

Dengue fever is a significant global health concern, classified as a neglected tropical disease. Already endemic in more than one hundred countries, it is spreading from tropical and subtropical regions to the Iberian Peninsula and the southern states of the US, partly attributed to climate change. As most cases are asymptomatic or mild, the actual numbers of dengue cases and deaths are under-reported. The disease's clinical course is divided into three phases: febrile, critical, and recovery. Severe dengue can develop suddenly, sometimes after a few days as the fever subsides, and is a medical emergency that can cause organ failure and death. Risk factors for severe dengue include chronic diseases such as asthma, sickle cell anemia, and diabetes mellitus, as well as female sex, older age (in adults), younger age (in children), and high body mass index. The development of vaccines and ongoing vector control efforts remain central to reducing its impact.

Did You Know?

• Dengue virus has four confirmed serotypes: DENV-1, DENV-2, DENV-3, and DENV-4.
• Infection with one serotype usually gives lifelong immunity to that type, but only short-term immunity to the others.

The Clinical Arc: From Fever to Recovery

Most people who contract dengue virus never realize they have been infected, with roughly eighty percent experiencing nothing beyond an uncomplicated fever. For those who do feel ill, the incubation window typically spans four to seven days—though it can stretch to fourteen—before a sudden wave of high fever, a headache centered behind the eyes, deep muscle and joint aches, nausea, vomiting, swollen glands, and a distinctive rash announce the febrile phase. This initial stage, with temperatures reaching forty to forty-one degrees Celsius, generally lasts two to seven days. For the vast majority, the critical phase never arrives. But in approximately five percent of infections, the disease escalates into what was once called dengue hemorrhagic fever or dengue shock syndrome. Plasma leaks from capillaries, platelet counts plummet, and blood pressure crashes, sometimes producing fluid pooling in the chest or abdomen, thickened blood, and multi-organ failure. Warning signs—severe abdominal pain, persistent vomiting, labored breathing, blood in the nose, gums, vomit, or stools—demand immediate hospitalization. Those who survive the critical window enter a recovery phase of two to three days, often marked by a striking, abrupt improvement accompanied by intense itching and a slowed heart rate.

The Four Serotypes and the Immunity Paradox

Dengue virus belongs to the Flaviviridae family and the Flavivirus genus, sharing that lineage with yellow fever, West Nile, and Zika viruses. Its genome is a relatively compact RNA strand of roughly eleven thousand nucleotide bases, encoding three structural proteins—C, prM, and E—that assemble the viral particle, plus seven additional proteins essential for replication. What makes dengue particularly insidious is the existence of four distinct serotypes, designated DENV-1 through DENV-4, distinguished by their antigenic profiles. Infection with one serotype confers lifelong immunity to that specific type but only brief, partial protection against the other three. This creates a dangerous paradox: a person who recovers from a DENV-1 infection and later encounters DENV-2 faces a heightened risk of severe complications. The mechanism behind this worsening, known as antibody-dependent enhancement, means that the very antibodies produced during the first infection can amplify the damage of a subsequent one. This serotype complexity is a central reason dengue remains so difficult to manage at a population level, and it directly shapes the design and limitations of available vaccines.

Fighting the Mosquito: Prevention and Treatment

Because no antiviral drug specifically targets dengue virus, clinical management is almost entirely supportive. In mild cases, treatment centers on relieving pain and managing fever. When the disease progresses to its severe form, hospitalization becomes essential; the cornerstone of care is restoring circulating fluid volume, administered orally or intravenously, to counteract the plasma leakage that drives shock and organ damage. Prevention, however, offers more concrete tools. The virus is transmitted almost exclusively by female mosquitoes of the Aedes genus, with Aedes aegypti as the principal vector, so eliminating breeding sites and preventing bites remain the most reliable strategies. Two vaccines have also entered the market. Diagnosis relies on blood tests that detect either viral RNA or specific antibodies, a step that can be complicated by the fact that dengue symptoms closely mimic those of malaria, influenza, or Zika.

A Neglected Epidemic on the Move

Yet it remains classified as a neglected tropical disease, a label that underscores the disproportionate gap between its global reach and the resources devoted to it. The situation is worsening. Because the majority of cases are asymptomatic or mild, true incidence and mortality figures are almost certainly under-reported. Climate change is increasingly cited as a driver pushing the disease's range beyond its traditional tropical and subtropical strongholds, with spread now documented on the Iberian Peninsula and in the southern states of the United States. Children and older adults face elevated complication risks, and concurrent infections with other tropical viruses such as Zika can compound severity. Pregnant women who contract dengue face heightened risks of miscarriage, low birth weight, and premature delivery—reminders that the disease's toll extends well beyond the individual patient.